We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
23.50 | 1.38% | 1,728.50 | 1,727.50 | 1,728.50 | 1,729.50 | 1,695.50 | 1,705.00 | 6,275,082 | 16:35:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.44 | 71.14B |
TIDMGSK
RNS Number : 7231S
GlaxoSmithKline PLC
10 July 2020
GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') ==== ========================================================================================= a) Name Mr N Hirons ==== ====================================== ================================================= b) Position/status SVP, Global Ethics & Compliance ==== ====================================== ================================================= c) Initial notification/ Initial notification amendment ==== ====================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== ========================================================================================= a) Name GlaxoSmithKline plc ==== ====================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ====================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== ========================================================================================= a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ====================================== ================================================= b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 9 July 2020. ==== ====================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ====================================== ========================= =================== GBP16.1054 11 ===================================================================== =================== d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================== ========================== e) Date of the transaction 2020-07-09 ==== ====================================== ================================================= f) Place of the London Stock Exchange (XLON) transaction ==== ====================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== ========================================================================================= a) Name Ms S Jackson ==== ====================================== ================================================= b) Position/status SVP, Global Communications & CEO Office ==== ====================================== ================================================= c) Initial notification/ Initial notification amendment ==== ====================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== ========================================================================================= a) Name GlaxoSmithKline plc ==== ====================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ====================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== ========================================================================================= a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ====================================== ================================================= b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 9 July 2020. ==== ====================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ====================================== ========================= =================== GBP16.1054 4 ===================================================================== =================== d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================== ========================== e) Date of the transaction 2020-07-09 ==== ====================================== ================================================= f) Place of the London Stock Exchange (XLON) transaction ==== ====================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== ============================================================================================= a) Name Mr D Jackson ==== ====================================== ===================================================== b) Position/status PCA of Ms S Jackson (SVP, Global Communications & CEO Office) ==== ====================================== ===================================================== c) Initial notification/ Initial notification amendment ==== ====================================== ===================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== ============================================================================================= a) Name GlaxoSmithKline plc ==== ====================================== ===================================================== b) LEI 5493000HZTVUYLO1D793 ==== ====================================== ===================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== ============================================================================================= a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ====================================== ===================================================== b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 9 July 2020. ==== ====================================== ===================================================== c) Price(s) and Price(s) Volume(s) volume(s) ==== ====================================== =========================== ===================== GBP16.1054 1 ======================================================================= ===================== d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ==================================================================== ============================ e) Date of the transaction 2020-07-09 ==== ====================================== ===================================================== f) Place of the London Stock Exchange (XLON) transaction ==== ====================================== ===================================================== 1. Details of PDMR/person closely associated with them ('PCA') ==== ========================================================================================= a) Name Ms V Whyte ==== ====================================== ================================================= b) Position/status Company Secretary
==== ====================================== ================================================= c) Initial notification/ Initial notification amendment ==== ====================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== ========================================================================================= a) Name GlaxoSmithKline plc ==== ====================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ====================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== ========================================================================================= a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ====================================== ================================================= b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 9 July 2020. ==== ====================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ====================================== ========================= =================== GBP16.1054 29 ===================================================================== =================== d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================== ========================== e) Date of the transaction 2020-07-09 ==== ====================================== ================================================= f) Place of the London Stock Exchange (XLON) transaction ==== ====================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== ========================================================================================= a) Name Mr I Whyte ==== ====================================== ================================================= b) Position/status PCA of Ms V A Whyte (Company Secretary) ==== ====================================== ================================================= c) Initial notification/ Initial notification amendment ==== ====================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== ========================================================================================= a) Name GlaxoSmithKline plc ==== ====================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ====================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== ========================================================================================= a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ====================================== ================================================= b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 9 July 2020. ==== ====================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ====================================== ========================= =================== GBP16.1054 883 ===================================================================== =================== d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================== ========================== e) Date of the transaction 2020-07-09 ==== ====================================== ================================================= f) Place of the London Stock Exchange (XLON) transaction ==== ====================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== ========================================================================================= a) Name Ms D Connor ==== ====================================== ================================================= b) Position/status PCA of Mr R G Connor (President, Global Vaccines) ==== ====================================== ================================================= c) Initial notification/ Initial notification amendment ==== ====================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== ========================================================================================= a) Name GlaxoSmithKline plc ==== ====================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ====================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== ========================================================================================= a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ====================================== ================================================= b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 9 July 2020. ==== ====================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ====================================== ========================= =================== GBP16.1054 455 ===================================================================== =================== d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================== ========================== e) Date of the transaction 2020-07-09 ==== ====================================== ================================================= f) Place of the London Stock Exchange (XLON) transaction ==== ====================================== =================================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHEBLFFBDLZBBB
(END) Dow Jones Newswires
July 10, 2020 11:41 ET (15:41 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions